Cardiology: Managing Cardiomyopathy and Arrhythmias

While mitochondrial disease often begins with hearing or metabolic changes, the heart is frequently involved because of its massive energy requirements ^[1]. In people with the m.3243A>G variant, cardiac issues can develop silently, meaning you may feel fine even while your heart muscle is changing ^[2]. Understanding how to monitor these changes and when to seek urgent care is a critical part of managing your health.

EMERGENCY ALERT: Urgent Cardiac Warning Signs

Because mitochondrial disease can affect the heart’s electrical system and its muscle structure, certain symptoms require immediate emergency intervention. Call 911 or local emergency services immediately if you experience:

• Syncope or Pre-syncope: Fainting, unexplained collapse, or severe dizziness feeling like you are about to pass out. Do not drive yourself if you experience this ^[3].
• Severe Shortness of Breath: New, rapidly worsening, or severe difficulty breathing, especially when lying flat or during light activity ^[3][4].
• Chest Pain/Pressure: Any unexplained pressure, tightness, or pain in the chest, particularly if it occurs during exertion ^[3].
• Sustained Palpitations: A racing, fluttering, or “skipping” heartbeat that is sustained or accompanied by dizziness or collapse ^[5].

Do not send a portal message or wait for a routine care team response for these severe symptoms. Reserve routine contact for mild, nonurgent changes.

Understanding Mitochondrial Cardiomyopathy

Cardiomyopathy is a general term for a disease of the heart muscle. In this condition, the muscle can change in various ways, and there is no inevitable or predictable sequence of progression ^[6].

• Hypertrophic Phenotype (HCM): The heart muscle becomes abnormally thick (hypertrophy). This impairs relaxation and filling, making the heart stiffer even if pumping strength initially remains normal ^[6][7].
• Dilated Phenotype (DCM): In some patients, the heart muscle may be thin and weakened, leading to enlarged (dilated) chambers and a weakened pump ^[6][1].
• Myocardial Fibrosis: Advanced imaging like Cardiac MRI can sometimes find microscopic scarring (fibrosis) in the heart muscle even before the heart’s pumping strength changes ^[2][4].

Your serial imaging and rhythm results determine what is happening in your heart.

Electrical Risks and Device Therapy

The m.3243A>G variant carries a significant risk for rhythm disturbances. In one historical cohort, up to 30% of patients had electrical pre-excitation like Wolff-Parkinson-White (WPW) syndrome, while many others developed slower conduction blocks ^[8]. It is important to distinguish between pre-excitation, slow conduction, and dangerous ventricular arrhythmias.
If your heart’s electrical system is significantly affected, your doctor may recommend device therapy. However, the variant alone is not an indication for a “preventative” pacemaker or ICD. Decisions depend on documented electrical disease, ventricular function, scar burden, symptoms, and arrhythmias:

• Pacemakers: To treat slow heart rates or advanced “blocks” ^[9].
• ICDs (Implantable Cardioverter Defibrillators): To protect against dangerous, rapid ventricular arrhythmias ^[3][10].

Standard Treatments for a Rare Condition

There is currently no “mitochondrial-specific” heart medication that has been proven to cure the condition ^[11]. Instead, doctors follow the same high-quality guidelines used for all forms of heart failure and cardiomyopathy ^[11][12].

• Medications: Treatments include beta-blockers, ACE inhibitors, or ARBs. However, these drugs have specific roles depending on whether you have obstructive disease, reduced ejection fraction, or hypertension. They are not universal preventatives for hypertrophy and can require caution in certain obstructive settings. Always follow your specific cardiac phenotype and guideline-based indications ^[13][11]. Do not start or stop these medicines without your cardiologist.
• Supplements: While many patients take Coenzyme Q10 (CoQ10) or L-carnitine, their effectiveness for the heart specifically is not yet supported by strong clinical evidence ^[14][15].

The Necessity of Comprehensive Screening

A standard ECG (Electrocardiogram) is a helpful tool but is not enough on its own to monitor a mitochondrial heart ^[16].

• The Gap: Research in a specific cohort showed that an ECG can miss structural heart disease in about 47% of cases, highlighting why multiple tests are needed ^[16].
• The Diagnostic Pathway: You should have regular echocardiograms (heart ultrasounds) to check the thickness and strength of the muscle ^[16][1]. Ambulatory monitoring (like a Holter monitor) is often used to check for silent arrhythmias. In many centers, a Cardiac MRI is used conditionally—when echocardiography is inadequate, findings change, or tissue characterization will alter management ^[2].
  Regular, proactive monitoring is the best way to ensure that any changes are caught early, allowing for treatments that protect your heart health over the long term.